LARVOL

How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with @Larvol. #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch #Cancer #CancerData #OncologyData | @brunolarvol

Immuno-Oncology (IO): Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #ImmunoOncology #Immunotherapy | @DrRishabhOnco | @DrChoueiri | @Erman_Akkus | @tompowles1 | @SuyogCancer | @DrYukselUrun | @GIMedOnc | @dr_yakupergun | @PTarantinoMD | @DrKarineTawagi | @HHorinouchi | @ChandrakanthMv | @jasonwilliamsmd | @DraMartinezLago | @GillSharlene

BsAb: Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BsAbs #BispecificAntibodies | @DrRishabhOnco | @Erman_Akkus | @SuyogCancer | @barriere_dr | @M_Torasawa | @HHorinouchi | @GIMedOnc | @DraMartinezLago | @tompowles1 | @FordePatrick | @GillSharlene | @ChandrakanthMv | @dr_yakupergun | @ErulEnes | @DrYukselUrun

ADC: Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #ADCs #AntibodyDrugConjugate | @PTarantinoMD | @DrRishabhOnco | @dr_yakupergun | @SuyogCancer | @tompowles1 | @ErikaHamilton9 | @MamMa_mimumemo | @Erman_Akkus | @HHorinouchi | @DrKarineTawagi | @ChandrakanthMv | @roxboxfix | @DrYukselUrun | @DrChoueiri | @GIMedOnc

GI Cancer: Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #ClinicalOncology | @Erman_Akkus | @GIMedOnc | @DraMartinezLago | @GillSharlene | @DaisukeKotani | @ilyassahinMD | @TapiaJC1 | @ArndtVogel | @Aiims1742 | @YannickBuccella | @DrAngelaLamarca | @CathyEngMD | @pashtoonkasi | @graokane | @UGrewalMD

GU Cancer: Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #ClinicalOncology | @DrChoueiri | @tompowles1 | @DrYukselUrun | @DrKarineTawagi | @amerseburger | @nataliagandur | @AndreaNecchi | @Dr_Aggen | @ShingoHatakeya1 | @shilpaonc | @PGrivasMDPhD | @TiansterZhang | @HimanshuNagarMD | @Kenrickng1 | @drmutluhizal

Breast Cancer: Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #ClinicalOncology | @PTarantinoMD | @dr_yakupergun | @ErikaHamilton9 | @MamMa_mimumemo | @barriere_dr | @Dr_Oncologista | @stolaney1 | @shimoi_oncology | @drsarahsam | @NeilVasan | @DrSGraff | @DrBarbiOnc | @hoperugo | @Dr_ElvinaA | @to_be_elizabeth

Lung Cancer: Top trending companies on 𝕏 during @myESMO 2026. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #LungCancer #SCLC #esSCLC #NSCLC #LCSM #ClinicalOncology | @HHorinouchi | @M_Torasawa | @FordePatrick | @RobertoBoreaMD | @GlopesMd | @DrRiyazShah | @FernandoOnco | @StephenVLiu | @tnewsomdavis | @dplanchard | @Latinamd | @Alfdoc2 | @ADesaiMD | @YGaritaonaindia | @g_mountzios

ES-SCLC maintenance: Is the treatment paradigm shifting? At @myESMO 2026, interim results from DeLLphi-305 showed a 58% relative reduction in the hazard of death with tarlatamab plus durvalumab versus durvalumab alone in first-line maintenance. ▶️ Among 563 patients without progression after induction therapy with durvalumab plus platinum-etoposide, the combination improved: 🔷 Median OS: 21.1 vs 12.7 months (HR 0.42) 🔷 Median PFS: 7.4 vs 1.9 months (HR 0.34) 🔷 Cytokine release syndrome occurred in 49.6% of patients receiving the combination, mostly grade 1–2; grade 3 occurred in 0.4%. ▶️ These findings build on IMforte, which showed improved median OS with lurbinectedin plus atezolizumab versus atezolizumab alone (13.2 vs 10.6 months; HR 0.73). The combination was FDA-approved in October 2025. 👉 Important: OS was measured from maintenance randomization in both trials, but cross-trial comparisons should be interpreted with caution. Superiority of tarlatamab plus durvalumab over lurbinectedin plus atezolizumab has not been established. What evidence will guide patient selection and sequencing as maintenance options expand? Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #LungCancer #esSCLC #LCSM #ClinicalOncology #FDA #FDAApproval | @StephenVLiu | @HHorinouchi | @FordePatrick | @RobertoBoreaMD | @Latinamd

🚨Breaking🚨 Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma roche.com/media/releases/med… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #Mesothelioma #MesotheliomaDiagnosis

LEAP-012 trial: Updated Data in Unres HCC: 10 vs TACE from @myESMO 2026, adapted from Dr. Stephen L. Chan (@StephenLChan1) 👉 nitter.cf/LorenzaRimassa/status/… Updated landscape 👉 clin.larvol.com/landscape/45… Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #HCC #HepatocellularCarcinoma #LEAP012 #Immunotherapy #LiverCancer #GastrointestinalCancer #GICancer #GICSM | @LorenzaRimassa | @pashtoonkasi | @ArndtVogel | @Erman_Akkus | @NiuSanford

🚨Breaking🚨 Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment abbott.mediaroom.com/2026-10… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MRDTest

🚨Breaking🚨 OGT launches first Fusion MRD NGS Panel for AML to expand fusion detection at MRD-level sensitivity ogt.com/about-us/news/ogt-la… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MRDTest #MRDTect #AcuteMyeloidLeukemia #Leukemia #LEUSM

🚨Breaking🚨 Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer businesswire.com/news/home/2… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #BreastCancer #BCSM | @stolaney1 | @ErikaHamilton9 | @PTarantinoMD | @curijoey | @dr_yakupergun | @hoperugo

FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulatio... fda.gov/drugs/resources-info… clin.larvol.com/trial-detail… #LARVOL #CancerResearch #OncologyInsights #ProstateCancer #HRRmutations #PARPinhibitor @DrChoueiri @nataliagandur @VivekSubbiah @DrYukselUrun

The Key Biomarkers Linked to Clinical Trials from @myESMO 2026 abstracts. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials | @tompowles1 | @HHorinouchi | @TiansterZhang | @Erman_Akkus

The Key Diagnostic Companies Linked to Clinical Trials from @myESMO 2026 abstracts. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials | @DrYukselUrun | @zklaassen_md | @Erman_Akkus | @PTarantinoMD | @StephenVLiu

The Key Diagnostic Tests Linked to Clinical Trials from @myESMO 2026 abstracts. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials | @DrYukselUrun | @zklaassen_md | @Erman_Akkus | @PTarantinoMD | @StephenVLiu

🚨Breaking🚨 Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leukemia businesswire.com/news/home/2… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #Leukemia #LEUSM

We're presenting a poster at @myESMO 2026! 🔷 A consensus-based large language model approach for predicting oncology clinical trial efficacy outcomes ▶️ Abstract ID: 134P 📍 Location: Poster Area - Hall 5 If you're attending ESMO 2026, stop by our poster and connect with us. Abstract link 👉 cslide.ctimeetingtech.com/es… Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials | @Davdwlkerson | @Krishnaveni_Y | @one_interrobang | @brunolarvol | @Jud_Prz

We're presenting a poster at @myESMO 2026! 🔷 LLM-based Evidence Scoring Framework: 1L non-exon 20 EGFR-mutated Advanced NSCLC as a Case Study ▶️ Abstract ID: 127P 📍 Location: Poster Area - Hall 5 If you're attending ESMO 2026, stop by our poster and connect with us. Abstract link 👉 cslide.ctimeetingtech.com/es… Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #LungCancer #NSCLC #LCSM | @5Reena_thakur | @one_interrobang | @brunolarvol | @Jud_Prz